STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #538 by analyst upside · 2026-08-13
GERN
Geron Corporation
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+170.7%
implied upside to consensus target
Current Price $1.57
Consensus Target $4.25
Bull Target $6.0
Bear Target $3.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
1
Sell
0
52-Week Low $1.04
52-Week High $2.01
YTD Return +18.9%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E 39.2x
EPS (TTM) $-0.11
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $205M
Profit Margin -33.1%
52-WEEK RANGE
52-Week Low $1.04
52-Week High $2.01
Current Price $1.57
Bear Target $3.0
Bull Target $6.0
● Now $1.57 ● Target $4.25
TRADING DATA
Avg Volume 12.4M
YTD Return +18.9%
Analyst Count 4
Consensus Buy
Upside to Target +170.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Geron Corporation (GERN) is currently trading at $1.57 with a Wall Street consensus price target of $4.25, implying potential upside of 170.7% over the next 12 months. 4 analysts currently cover GERN, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.0, while the most cautious has a target of $3.0.

GERN operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 18.9% year-to-date and is currently trading near the upper end of its 52-week range of $1.04 – $2.01.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for GERN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Needham - Reiterated
Buy → Buy 2025-11-05 20% win rate (5 calls)
Scotiabank ↓ Downgrade
Sector Outperform → Sector Perform 2025-05-08 20% win rate (5 calls)
Needham reit
Buy → Buy 2025-03-12 20% win rate (5 calls)
HC Wainwright & Co. reit
Neutral → Neutral 2025-03-12 31% win rate (48 calls)
Scotiabank - Reiterated
Sector Outperform → Sector Outperform 2025-02-27 20% win rate (5 calls)
Stifel - Reiterated
Buy → Buy 2025-02-27 Building track record
Barclays - Reiterated
Overweight → Overweight 2025-02-27 Building track record
Needham - Reiterated
Buy → Buy 2025-02-27 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
26
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →